Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Lusutrombopag

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Shionogi launches thrombocytopenia treatment Mulpleo in the UK
    Shionogi launches thrombocytopenia treatment Mulpleo in the UK

    11 Mar 2020

    // Lucy Parsons PM LIVE

    http://www.pmlive.com/pharma_news/shionogi_launches_thrombocytopenia_treatment_mulpleo_in_the_uk_1328598

    Lucy Parsons PM LIVE
    11 Mar 2020
    Share Share
    Shionogi's Lusutrombopag Receives Approval in Europe
    Shionogi's Lusutrombopag Receives Approval in Europe

    22 Mar 2019

    // EMA

    https://www.ema.europa.eu/documents/product-information/lusutrombopag-shionogi-epar-product-information_en.pdf

    EMA
    22 Mar 2019
    Share Share
    Lusutrombopag gets EU green light for liver disease
    Lusutrombopag gets EU green light for liver disease

    26 Feb 2019

    // Anna Smith PHARMA TIMES

    http://www.pharmatimes.com/news/unreasonable_prescription_costs_leading_to_life-threatening_asthma_attacks_1279439

    Anna Smith PHARMA TIMES
    26 Feb 2019
    Share Share
    Committee for Orphan Medicinal Products report on orphan designation review
    Committee for Orphan Medicinal Products report on orphan designation review

    17 Dec 2018

    //

    https://www.ema.europa.eu/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-december-2018_en.pdf

    17 Dec 2018
    Share Share
    Meeting highlights from the CHMP 10-13 December 2018
    Meeting highlights from the CHMP 10-13 December 2018

    14 Dec 2018

    //

    https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018

    14 Dec 2018
    Share Share
    Shionogi Announces FDA Approval of Mulpleta® (Lusutrombopag)
    Shionogi Announces FDA Approval of Mulpleta® (Lusutrombopag)

    01 Aug 2018

    // PRESS RELEASE

    http://www.shionogi.com/newsroom/article.html#122532

    PRESS RELEASE
    01 Aug 2018
    Share Share